, Volume 9, Issue 1, pp 51–56 | Cite as

Clinical implications of molecular studies for the diagnosis of thyroid cancer

  • Markus Eszlinger
  • Kurt Werner Schmid
  • Ralf PaschkeEmail author
Mini Review


  1. 1.
    DeLellis RA, Williams ED, LiVolsi V, et al 2004 Tumours of the Thyroid and Parathyroid. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) WHO Classification of Tumours: Pathology & Genetics of Tumours of Endocrine Organs, Lyon: IARC Press; pp, 51–103.Google Scholar
  2. 2.
    Williams ED 2000 Guest Editorial: Two Proposals Regarding the Terminology of Thyroid Tumors. Int J Surg Pathol 8: 181–183.CrossRefGoogle Scholar
  3. 3.
    Frates MC, Benson CB, Charboneau JW, et al, 2005 Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 237: 794–800.CrossRefGoogle Scholar
  4. 4.
    Varverakis E, Neonakis E, 2002 Contribution of high-resolution ultrasonography in the differential diagnosis of benign from malignant thyroid nodules. Hormones (Athens) 1: 51–56.Google Scholar
  5. 5.
    Gharib H, 1997 Changing concepts in the diagnosis and management of thyroid nodules. Endocrinol Metab Clin North Am 26: 777–800.CrossRefGoogle Scholar
  6. 6.
    Carpi A, Ferrari E, Toni MG, et al, 1996 Needle aspiration techniques in preoperative selection of patients with thyroid nodules: a long-term study. J Clin Oncol 14: 1704–1712.CrossRefGoogle Scholar
  7. 7.
    Lowhagen T, Granberg PO, Lundell G, et al, 1979 Aspiration biopsy cytology (ABC) in nodules of the thyroid gland suspected to be malignant. Surg Clin North Am 59: 3–18.CrossRefGoogle Scholar
  8. 8.
    Schmid KW, Farid NR, 2006 How to define follicular thyroid carcinoma? Virchows Arch 448: 385–393.CrossRefGoogle Scholar
  9. 9.
    Chan JKC, Hirokawa, M, Evans H, et al 2004 Tumours of the Thyroid and Parathyroid: Follicular adenoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) WHO Classification of Tumours: Pathology & Genetics of Tumours of Endocrine Organs, Lyon: IARCPress; pp, 98–103.Google Scholar
  10. 10.
    Franc B, de la Salmoniere P, Lange F, et al, 2003 Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma. Hum Pathol 34: 1092–1100.CrossRefGoogle Scholar
  11. 11.
    Lang W, Georgii A, Stauch G, Kienzle E, 1980 The differentiation of atypical adenomas and encapsulated follicular carcinomas in the thyroid gland. Virchows Arch. A Pathol Anat Histol 385: 125–141.CrossRefGoogle Scholar
  12. 12.
    Lang W, Choritz H, Hundeshagen H, 1986 Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings. Am J Surg Pathol 10: 246–255.CrossRefGoogle Scholar
  13. 13.
    Schmid KW, Totsch M, Ofner D, et al, 1997 Minimally invasive follicular thyroid carcinoma: a clinico-pathological study. Curr Top Pathol 91: 37–43.CrossRefGoogle Scholar
  14. 14.
    Faggiano A, Caillou B, Lacroix L, et al, 2007 Functional characterization of human thyroid tissue with immunohistochemistry. Thyroid 17: 203–211.CrossRefGoogle Scholar
  15. 15.
    Paschke R, Ludgate M, 1997 The thyrotropin receptor in thyroid diseases. N Engl J Med 337: 1675–1681.CrossRefGoogle Scholar
  16. 16.
    Trulzsch B, Krohn K, Wonerow P, et al,2001 Detection of thyroid-stimulating hormone receptor and Gsalpha mutations: in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis. J Mol Med 78: 684–691.CrossRefGoogle Scholar
  17. 17.
    Sykiotis PG, Sgourou A, Papachatzopoulou A, et al, 2002 A somatic mutation in the thyrotropin receptor gene in a patient with an autonomous nodule within a mulitnodular goiter. Hormones (Athens) 1: 42–46.CrossRefGoogle Scholar
  18. 18.
    Fagin JA, 2002 Mini review: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol 16: 903–911.PubMedGoogle Scholar
  19. 19.
    Kondo T, Ezzat S, Asa SL, 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6: 292–306.CrossRefGoogle Scholar
  20. 20.
    Chung KW, Yang SK, Lee GK, et al, 2006 Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) 65: 660–666.CrossRefGoogle Scholar
  21. 21.
    Tetzlaff MT, LiVolsi V, Baloch ZW, 2006 Assessing the utility of a mutational assay for B-RAF as an adjunct to conventional fine needle aspiration of the thyroid gland. Adv Anat Pathol 13: 228–237.CrossRefGoogle Scholar
  22. 22.
    Cohen Y, Rosenbaum E, Clark DP, et al, 2004 Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res 10: 2761–2765.CrossRefGoogle Scholar
  23. 23.
    Jin L, Sebo TJ, Nakamura N, et al, 2006 BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 15: 136–143.CrossRefGoogle Scholar
  24. 24.
    Pizzolanti G, Russo L, Richiusa P, et al, 2007 Fine-need le aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF(V600E) mutation and RET/PTC rearrangement. Thyroid 17: 1109–1115.CrossRefGoogle Scholar
  25. 25.
    Rowe LM, Bentz BM, Bentz JM, 2006 Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. Cytojournal 3: 10.CrossRefGoogle Scholar
  26. 26.
    Salvatore G, Giannini R, Faviana P, et al, 2004 Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89: 5175–5180.CrossRefGoogle Scholar
  27. 27.
    Sapio MR, Posca D, Raggioli A, et al, 2007 Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol (Oxf) 66: 678–683.CrossRefGoogle Scholar
  28. 28.
    Kim KH, Kang DW, Kim SH, et al, 2004 Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45: 818–821.CrossRefGoogle Scholar
  29. 29.
    Kim TY, Kim WB, Song JY, et al, 2005 The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clinical Endocrinology 63: 588–593.CrossRefGoogle Scholar
  30. 30.
    Trulzsch B, Krohn K, Wonerow P, Paschke R, 1999 DGGE is more sensitive for the detection of somatic point mutations than direct sequencing. Biotechniques 27: 266–268.PubMedCrossRefGoogle Scholar
  31. 31.
    Zhu Z, Ciampi R, Nikiforova MN, et al, 2006 Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab 91: 3603–3610.CrossRefGoogle Scholar
  32. 32.
    Rhoden KJ, Unger K, Salvatore G, et al, 2006 RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto’s thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab 91: 2414–2423.CrossRefGoogle Scholar
  33. 33.
    Cheung L, Messina M, Gill A, et al, 2003 Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 88: 354–357.CrossRefGoogle Scholar
  34. 34.
    Marques AR, Espadinha C, Catarino AL, et al, 2002 Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 87: 3947–3952.PubMedGoogle Scholar
  35. 35.
    Nikiforova MN, Biddinger PW, Caudill CM, et al, 2002 PA X8-PPA Rgamma rea r rangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26: 1016–1023.CrossRefGoogle Scholar
  36. 36.
    Eszlinger M, Krohn K, Kukulska A, et al, 2007 Perspectives and Limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors. Endocr Rev 28: 322–338.CrossRefGoogle Scholar
  37. 37.
    Aogi K, Kitahara K, Buley I, et al, 1998 Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates. Clin Cancer Res 4: 1965–1970.PubMedGoogle Scholar
  38. 38.
    Bernet VJ, Anderson J, Vaishnav Y, et al, 2002 Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 87: 4792–4796.CrossRefGoogle Scholar
  39. 39.
    Casey MB, Lohse CM, Lloyd RV, 2003 Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol 14: 55–60.CrossRefGoogle Scholar
  40. 40.
    Haugen BR, Nawaz S, Markham N, et al, 1997 Telomerase activity in benign and malignant thyroid tumors. Thyroid 7: 337–342.CrossRefGoogle Scholar
  41. 41.
    Inohara H, Honjo Y, Yoshii T, et al, 1999 Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85: 2475–2484.CrossRefGoogle Scholar
  42. 42.
    Ippolito A, Vella V, La Rosa GL, et al, 2001 Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy. Thyroid 11: 783–787.CrossRefGoogle Scholar
  43. 43.
    Mase T, Funahashi H, Koshikawa T, et al, 2003 HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm. Endocr J 50: 173–177.CrossRefGoogle Scholar
  44. 44.
    Raphael SJ, 2002 The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia. Endocr Pathol 13: 301–311.CrossRefGoogle Scholar
  45. 45.
    Sack MJ, Astengo-Osuna C, Lin BT, et al, 1997 HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 10: 668–674.PubMedGoogle Scholar
  46. 46.
    Saggiorato E, Cappia S, De Giuli P, et al, 2001 Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 86: 5152–5158.CrossRefGoogle Scholar
  47. 47.
    Huang Y, Prasad M, Lemon WJ, et al, 2001 Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U.S.A. 98: 15044–15049.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Jarzab B, Wiench M, Fujarewicz K, et al, 2005 Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65: 1587–1597.CrossRefGoogle Scholar
  49. 49.
    Kholova I, Ryska A, Ludvikova M, et al, 2003 Dipeptidyl peptidase IV expression in thyroid cytology: retrospective histologically confirmed study. Cytopathology 14: 27–31.CrossRefGoogle Scholar
  50. 50.
    Giannini R, Faviana P, Cavinato T, et al, 2003 Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid 13: 765–770.CrossRefGoogle Scholar
  51. 51.
    Papotti M, Rodriguez J, De Pompa R, et al, 2005 Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Mod Pathol 18: 541–546.CrossRefGoogle Scholar
  52. 52.
    Prasad ML, Huang Y, Pellegata NS, et al, 2004 Hashimoto’s thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology 45: 39–46.CrossRefGoogle Scholar
  53. 53.
    Saggiorato E, De Pompa R, Volante M, et al, 2005 Characterization of thyroid ‘follicular neoplasms’ in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer 12: 305–317.CrossRefGoogle Scholar
  54. 54.
    Takano T, Miyauchi A, Matsuzuka F, et al, 2000 Expression of oncofetal fibronectin messenger ribonucleic acid in fibroblasts in the thyroid: a possible cause of false positive results in molecular-based diagnosis of thyroid carcinomas. J Clin Endocrinol Metab 85: 765–768.PubMedGoogle Scholar
  55. 55.
    Krause K, Eszlinger M, Gimm O, et al, 2008 TFF 3 based candidate gene discrimination of benign and malignant thyroid tumours in a region with borderline iodine deficiency. J Clin Endocrinol Metab 93: 1390–1393.CrossRefGoogle Scholar
  56. 56.
    Eszlinger M, Wiench M, Jarzab B, et al, 2006 Meta- and reanalysis of gene expression profiles of hot and cold thyroid nodules and papillary thyroid carcinoma for gene groups. J Clin Endocrinol Metab 91: 1934–1942.CrossRefGoogle Scholar
  57. 57.
    Fujarewicz K, Jarzab M, Eszlinger M, et al, 2007 A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping. Endocr Relat Cancer 14: 809–826.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Kebebew E, Peng M, Reiff E, McMillan A, 2006 Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer 106: 2592–2597.CrossRefGoogle Scholar
  59. 59.
    Mazzanti C, Zeiger MA, Costouros NG, et al, 2004 Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64: 2898–2903.CrossRefGoogle Scholar
  60. 60.
    Sapio MR, Guerra A, Posca D, et al, 2007 Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer 14: 1089–1097.CrossRefGoogle Scholar
  61. 61.
    Cerutti JM, Delcelo R, Amadei MJ, et al, 2004 A pre-operative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113: 1234–1242.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Weber F, Shen L, Aldred MA, et al, 2005 Genetic classification of benign and malignant thyroid follicular neoplasia based on a 3-gene combination. J Clin Endocrinol Metab 90: 2512–2521.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2010

Authors and Affiliations

  • Markus Eszlinger
    • 1
  • Kurt Werner Schmid
    • 2
  • Ralf Paschke
    • 1
    Email author
  1. 1.3rd Medical DepartmentUniversity of LeipzigLeipzigGermany
  2. 2.Institute of Pathology and NeuropathologyUniversity Hospital of Essen, University of Duisburg-EssenEssenGermany

Personalised recommendations